Journal of Neuroscience · 2004 · 167 citations · 45 references
Life SciencesNeurosciencePharmacologyInflammationNeurodegenerationNeuropharmacologyAlzheimer DiseaseAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeuroprotectionAlzheimer Disease NeuroprotectionAmyloid Beta PlaquesAmyloid PlaquesAmyloid ToxicityLow-molecular-weight Heparin TherapyNeuroinflammation In Alzheimer DiseaseProinflammatory MediatorsTransgenic Mice
We investigated the effect of long-term, peripheral treatment with enoxaparin, a low molecular weight heparin, in transgenic mice overexpressing human amyloid precursor protein(751). Enoxaparin (6 IU per mouse intraperitoneally, three times a week for 6 months) significantly lowered the number and the area occupied by cortical beta-amyloid deposits and the total beta-amyloid (1-40) cortical concentration. Immunocytochemical analysis of glial fibrillary acid protein-positive cells showed that enoxaparin markedly reduced the number of activated astrocytes surrounding beta-amyloid deposits. In vitro, the drug dose-dependently attenuated the toxic effect of beta-amyloid on neuronal cells. Enoxaparin dose-dependently reduced the ability of beta-amyloid to activate complement and contact systems, two powerful effectors of inflammatory response in AD brain. By reducing the beta-amyloid load and cytotoxicity and proinflammatory activity, enoxaparin offers promise as a tool for slowing the progression of Alzheimer's disease.
45
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Dale Schenk, Robin Barbour, Whitney Dunn et al. · Nature · 1999 · 3.2K citations
Ronald B. DeMattos, Kelly R. Bales, David J. Cummins et al. · Proceedings of the National Academy of Sciences · 2001 · 1.3K citations · Full text
Pharmacy, Neurobiology, Neuroscience +17